Literature DB >> 20811074

Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples.

Marcel P Stoop1, Leon Coulier, Therese Rosenling, Shanna Shi, Agnieszka M Smolinska, Lutgarde Buydens, Kirsten Ampt, Christoph Stingl, Adrie Dane, Bas Muilwijk, Ronald L Luitwieler, Peter A E Sillevis Smitt, Rogier Q Hintzen, Rainer Bischoff, Sybren S Wijmenga, Thomas Hankemeier, Alain J van Gool, Theo M Luider.   

Abstract

The analysis of cerebrospinal fluid (CSF) is used in biomarker discovery studies for various neurodegenerative central nervous system (CNS) disorders. However, little is known about variation of CSF proteins and metabolites between patients without neurological disorders. A baseline for a large number of CSF compounds appears to be lacking. To analyze the variation in CSF protein and metabolite abundances in a number of well-defined individual samples of patients undergoing routine, non-neurological surgical procedures, we determined the variation of various proteins and metabolites by multiple analytical platforms. A total of 126 common proteins were assessed for biological variations between individuals by ESI-Orbitrap. A large spread in inter-individual variation was observed (relative standard deviations [RSDs] ranged from 18 to 148%) for proteins with both high abundance and low abundance. Technical variation was between 15 and 30% for all 126 proteins. Metabolomics analysis was performed by means of GC-MS and nuclear magnetic resonance (NMR) imaging and amino acids were specifically analyzed by LC-MS/MS, resulting in the detection of more than 100 metabolites. The variation in the metabolome appears to be much more limited compared with the proteome: the observed RSDs ranged from 12 to 70%. Technical variation was less than 20% for almost all metabolites. Consequently, an understanding of the biological variation of proteins and metabolites in CSF of neurologically normal individuals appears to be essential for reliable interpretation of biomarker discovery studies for CNS disorders because such results may be influenced by natural inter-individual variations. Therefore, proteins and metabolites with high variation between individuals ought to be assessed with caution as candidate biomarkers because at least part of the difference observed between the diseased individuals and the controls will not be caused by the disease, but rather by the natural biological variation between individuals.

Entities:  

Mesh:

Year:  2010        PMID: 20811074      PMCID: PMC2938111          DOI: 10.1074/mcp.M900877-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  35 in total

1.  Attomole peptide analysis by high-pressure matrix-assisted laser desorption/ionization Fourier transform mass spectrometry.

Authors:  Susanne C Moyer; Bogdan A Budnik; Jason L Pittman; Catherine E Costello; Peter B O'Connor
Journal:  Anal Chem       Date:  2003-12-01       Impact factor: 6.986

Review 2.  Biological markers of the inflammatory phase of multiple sclerosis.

Authors:  A Uccelli; E Pedemonte; E Narciso; G Mancardi
Journal:  Neurol Sci       Date:  2003-12       Impact factor: 3.307

Review 3.  CSF proteome: a protein repository for potential biomarker identification.

Authors:  Martin J Romeo; Virginia Espina; Mark Lowenthal; Benjamin H Espina; Emanuel F Petricoin; Lance A Liotta
Journal:  Expert Rev Proteomics       Date:  2005-01       Impact factor: 3.940

4.  Changes in the cerebrospinal-fluid monoamines in rats with an immunoneutralization of the subcommissural organ-Reissner's fiber complex by maternal delivery of antibodies.

Authors:  S Rodríguez; K Vio; C Wagner; M Barría; E H Navarrete; V D Ramírez; J M Pérez-Fígares; E M Rodríguez
Journal:  Exp Brain Res       Date:  1999-10       Impact factor: 1.972

5.  600 MHz 1H-NMR spectroscopy of human cerebrospinal fluid: effects of sample manipulation and assignment of resonances.

Authors:  B C Sweatman; R D Farrant; E Holmes; F Y Ghauri; J K Nicholson; J C Lindon
Journal:  J Pharm Biomed Anal       Date:  1993-08       Impact factor: 3.935

6.  Simultaneous assay of prostaglandins and thromboxane in the cerebrospinal fluid by gas chromatography-mass spectrometry-selected ion monitoring.

Authors:  T Obata; T Nagakura; H Maeda; K Yamashita; K Maekawa
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-08-06

7.  Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid.

Authors:  Yan Hu; James P Malone; Anne M Fagan; R Reid Townsend; David M Holtzman
Journal:  Mol Cell Proteomics       Date:  2005-09-30       Impact factor: 5.911

8.  CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone.

Authors:  S T Frequin; F Barkhof; K J Lamers; O R Hommes; G F Borm
Journal:  Acta Neurol Scand       Date:  1992-09       Impact factor: 3.209

9.  Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease.

Authors:  D Lefranc; P Vermersch; J Dallongeville; C Daems-Monpeurt; H Petit; A Delacourte
Journal:  Neurosci Lett       Date:  1996-07-12       Impact factor: 3.046

Review 10.  Immunology of multiple sclerosis.

Authors:  K C Williams; E Ulvestad; W F Hickey
Journal:  Clin Neurosci       Date:  1994
View more
  45 in total

1.  CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Authors:  Astrid Guldbrandsen; Yehia Farag; Ann Cathrine Kroksveen; Eystein Oveland; Ragnhild R Lereim; Jill A Opsahl; Kjell-Morten Myhr; Frode S Berven; Harald Barsnes
Journal:  Mol Cell Proteomics       Date:  2016-11-27       Impact factor: 5.911

Review 2.  Analysis of bacterial biofilms using NMR-based metabolomics.

Authors:  Bo Zhang; Robert Powers
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

Review 3.  Recent advances in quantitative neuroproteomics.

Authors:  George E Craft; Anshu Chen; Angus C Nairn
Journal:  Methods       Date:  2013-04-25       Impact factor: 3.608

Review 4.  Circulating glioma biomarkers.

Authors:  Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

5.  Assessment of Blood Contamination in Biological Fluids Using MALDI-TOF MS.

Authors:  Katrina Laks; Tiina Kirsipuu; Tuuli Dmitrijeva; Andres Salumets; Peep Palumaa
Journal:  Protein J       Date:  2016-06       Impact factor: 2.371

Review 6.  What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?

Authors:  Christoph W Turck; Michaela D Filiou
Journal:  Mol Neuropsychiatry       Date:  2015-05-12

7.  Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Authors:  Alberto Lleó; Raúl Núñez-Llaves; Daniel Alcolea; Cristina Chiva; Daniel Balateu-Paños; Martí Colom-Cadena; Gemma Gomez-Giro; Laia Muñoz; Marta Querol-Vilaseca; Jordi Pegueroles; Lorena Rami; Albert Lladó; José L Molinuevo; Mikel Tainta; Jordi Clarimón; Tara Spires-Jones; Rafael Blesa; Juan Fortea; Pablo Martínez-Lage; Raquel Sánchez-Valle; Eduard Sabidó; Àlex Bayés; Olivia Belbin
Journal:  Mol Cell Proteomics       Date:  2019-01-03       Impact factor: 5.911

Review 8.  Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.

Authors:  Nardin Samuel; Marc Remke; James T Rutka; Brian Raught; David Malkin
Journal:  J Neurooncol       Date:  2014-04-26       Impact factor: 4.130

9.  Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.

Authors:  Son N Nguyen; Cedric E Bobst; Igor A Kaltashov
Journal:  Mol Pharm       Date:  2013-04-10       Impact factor: 4.939

10.  Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS.

Authors:  Yoshio Araki; Kazuhiro Yoshikawa; Sho Okamoto; Masaki Sumitomo; Mikio Maruwaka; Toshihiko Wakabayashi
Journal:  BMC Neurol       Date:  2010-11-08       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.